Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergens.
Stingeni L, Bianchi L, Caroppo ES, Belloni Fortina A, Caroppo F, Corazza M, Borghi A, Gallo R, Trave I, Ferrucci SM, Beretta A, Guarneri F, Martina E, Napolitano M, DE Lucia M, Patruno C, Bennardo L, Romita P, Foti C, Tramontana M, Marietti R, Argenziano G, Hansel K; Skin Allergy group of SIDeMaST and Società Italiana di Dermatologia Allergologica, Professionale e Ambientale (SIDAPA). Stingeni L, et al. Ital J Dermatol Venerol. 2024 Apr;159(2):83-104. doi: 10.23736/S2784-8671.24.07733-8. Ital J Dermatol Venerol. 2024. PMID: 38650492
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Perrino M, Voulaz E, Balin S, Cazzato G, Fontana E, Franzese S, Defendi M, De Vincenzo F, Cordua N, Tamma R, Borea F, Aliprandi M, Airoldi M, Cecchi LG, Fazio R, Alloisio M, Marulli G, Santoro A, Di Tommaso L, Ingravallo G, Russo L, Da Rin G, Villa A, Della Bella S, Zucali PA, Mavilio D. Perrino M, et al. Among authors: fontana e. Front Immunol. 2024 Apr 2;15:1288045. doi: 10.3389/fimmu.2024.1288045. eCollection 2024. Front Immunol. 2024. PMID: 38629065 Free PMC article. Review.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P, Deville JL, Pouessel D, Yoon S, Powles T, Bernat M, Häckl M, Marszewska M, McKernan P, Saulay M, Scaleia F, Engelhardt M, Loriot Y, Siefker-Radtke A, De Santis M. Necchi A, et al. Among authors: fontana e. JNCI Cancer Spectr. 2024 Apr 16:pkae030. doi: 10.1093/jncics/pkae030. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 38627238
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers.
Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, Lenz HJ, Shields AF, Nabhan C, Oberley M, Seeber A, El-Deiry W. Lou E, et al. Among authors: fontana e. Mol Ther Oncol. 2024 Feb 28;32(1):200786. doi: 10.1016/j.omton.2024.200786. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596288 Free PMC article.
Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer.
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, Ghelardi F, Sottotetti E, Vetere G, Ciraci P, Vlachogiannis G, Pietrantonio F, Cremolini C, Cortellini A, Loupakis F, Fassan M, Valeri N. Hedayat S, et al. Among authors: fontana e. Clin Cancer Res. 2024 Feb 20. doi: 10.1158/1078-0432.CCR-23-2748. Online ahead of print. Clin Cancer Res. 2024. PMID: 38376926
[Endocrinology: what's new in 2023].
Ameti A, Chouchane K, Fontana E, Papadakis GE. Ameti A, et al. Among authors: fontana e. Rev Med Suisse. 2024 Jan 17;20(856-7):36-41. doi: 10.53738/REVMED.2024.20.856-7.36. Rev Med Suisse. 2024. PMID: 38231097 Review. French.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
Rosen E, Yap TA, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Plummer R, Fretland AJ, Ulanet D, Xu Y, McDougall R, Koehler M, Fontana E. Rosen E, et al. Among authors: fontana e. Clin Cancer Res. 2024 Feb 16;30(4):687-694. doi: 10.1158/1078-0432.CCR-23-2080. Clin Cancer Res. 2024. PMID: 38078898 Free PMC article.
323 results